Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.
We report two cases with B cell malignancies (case #1: refractory mantle cell lymphoma; case #2: lymphocyte predominant Hodgkin's disease (LPHD)) who developed neutropenia post-Rituximab therapy in a setting of significant infiltration of the peripheral blood (PB) and bone marrow (BM) by T cells with an immunophenotype of large granular lymphocytes. Possible pathogenetic mechanisms are discussed.
Papadaki
T
T
Hemopathology Unit, Evangelismos Hospital, Athens, Greece.
Stamatopoulos
K
K
Stavroyianni
N
N
Paterakis
G
G
Phisphis
M
M
Stefanoudaki-Sofianatou
K
K
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced* / Q000209:etiology; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; D000069283:Rituximab